AstraZeneca Reports 58% Lower Death Risk With Durvalumab-Tarlatamab in Phase III
AstraZeneca said the combination cut the risk of death by 58% versus IMFINZI alone in first-line maintenance ES-SCLC. Median overall survival was 21.1 months versus 12.7 months; progression or death risk fell 66%.
AstraZeneca said IMFINZI (durvalumab) plus Amgen’s tarlatamab-dlle cut risk of death by 58% vs IMFINZI alone in 1L maintenance ES—SCLC (OS HR 0.42; p<0.001) and reduced progression/death risk by 66% (PFS HR 0.34; p<0.001). Median OS 21.1 vs 12.7 months.Material DetailsContext by AI AnalystThis is l…